Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
Federal funding cuts imperil next generation of autism researchers
As the International Society for Autism Research’s annual meeting begins, its next president reflects on a brewing crisis.
Federal funding cuts imperil next generation of autism researchers
As the International Society for Autism Research’s annual meeting begins, its next president reflects on a brewing crisis.
Null and Noteworthy: Reanalysis contradicts report of immune memory in astrocytes
The analysis, which has not yet been peer reviewed, attributes the finding to misidentified immune cells instead.
Null and Noteworthy: Reanalysis contradicts report of immune memory in astrocytes
The analysis, which has not yet been peer reviewed, attributes the finding to misidentified immune cells instead.
Documenting decades of autism prevalence; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 28 April.
Documenting decades of autism prevalence; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 28 April.